GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes.

[1]  N. Sattar,et al.  GLP-1 Receptor Agonists for the Reduction of Atherosclerotic Cardiovascular Risk in Patients With Type 2 Diabetes. , 2022, Circulation.

[2]  R. Gabbay,et al.  Management of hyperglycaemia in type 2 diabetes, 2022. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) , 2022, Diabetologia.

[3]  R. Gabbay,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). , 2022, Diabetes care.

[4]  F. Zannad,et al.  Risk of adverse events with liraglutide in heart failure with reduced ejection fraction: A post hoc analysis of the FIGHT trial , 2022, Diabetes, obesity & metabolism.

[5]  M. Link,et al.  2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. , 2022, Journal of the American College of Cardiology.

[6]  P. Light,et al.  Cardiac mechanisms of the beneficial effects of SGLT2 inhibitors in heart failure: Evidence for potential off-target effects. , 2022, Journal of molecular and cellular cardiology.

[7]  J. McMurray,et al.  2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure , 2022, European journal of heart failure.

[8]  J. Rosenstock,et al.  Efpeglenatide and Clinical Outcomes With and Without Concomitant Sodium-Glucose Cotransporter-2 Inhibition Use in Type 2 Diabetes: Exploratory Analysis of the AMPLITUDE-O Trial , 2021, Circulation.

[9]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. , 2021, The lancet. Diabetes & endocrinology.

[10]  H. Heerspink,et al.  SGLT2 inhibitors and GLP-1 receptor agonists: established and emerging indications , 2021, The Lancet.

[11]  Sandeep R. Das,et al.  2020 Expert Consensus Decision Pathway on Novel Therapies for Cardiovascular Risk Reduction in Patients With Type 2 Diabetes: A Report of the American College of Cardiology Solution Set Oversight Committee. , 2020, Journal of the American College of Cardiology.

[12]  J. McMurray,et al.  Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. , 2019, The lancet. Diabetes & endocrinology.

[13]  B. Zinman,et al.  Semaglutide once weekly as add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9): a randomised, placebo-controlled trial. , 2019, The lancet. Diabetes & endocrinology.

[14]  P. Wilson,et al.  Diabetes Mellitus–Related All‐Cause and Cardiovascular Mortality in a National Cohort of Adults , 2019, Journal of the American Heart Association.

[15]  M. Roden,et al.  GLP-1 receptor agonists and cardiovascular disease: drug-specific or class effects? , 2019, The lancet. Diabetes & endocrinology.

[16]  Marc P. Bonaca,et al.  SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials , 2019, The Lancet.

[17]  Diane M. Miller,et al.  Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. , 2018, Lancet.

[18]  Lawrence A Leiter,et al.  Harmony Outcomes: A randomized, double‐blind, placebo‐controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus—Rationale, design, and baseline characteristics , 2018, American heart journal.

[19]  J. McMurray,et al.  SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review , 2018, Diabetologia.

[20]  B. Ludvik,et al.  Dulaglutide as add-on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. , 2018, The lancet. Diabetes & endocrinology.

[21]  G. Hindricks,et al.  2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). , 2018, European heart journal.

[22]  L. Tarnow,et al.  Effect of liraglutide, a glucagon‐like peptide‐1 analogue, on left ventricular function in stable chronic heart failure patients with and without diabetes (LIVE)—a multicentre, double‐blind, randomised, placebo‐controlled trial , 2017, European journal of heart failure.

[23]  K. Anstrom,et al.  Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial. , 2016, JAMA.

[24]  D. Altman,et al.  Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.

[25]  S. Thompson,et al.  Quantifying heterogeneity in a meta‐analysis , 2002, Statistics in medicine.